Metropolis Healthcare Limited — Investor Meet, 16-12-2024: Analysts/Institutional Investor Meet/Con. Call Updates

**Financial Performance:** Metropolis Healthcare's acquisition of Core Diagnostics, valued at INR 246.8 crore, positions the firm strategically within the fast-growing oncology diagnostics market in India. The overall revenue generated by Core has shown a robust CAGR of around 22% for FY22-FY24, with an average revenue per test of INR 2,300. It operated at a marginal profit as of H1 FY24, with a reported revenue of INR 59 crore. The acquisition is expected to be EPS-accretive from FY26, with anticipated ROCE and ROE improvements by FY28.

**Future Outlook and Growth Drivers:** Management highlights the oncology diagnostics market's potential, forecasting a CAGR of 17.5% in the next five years, driven by increased cancer incidence and healthcare awareness. The integration of Core’s specialized services enables Metropolis to leverage economies of scale, expected to enhance profitability over time.

**Order Book and Operational Updates:** Core operates over 1,300 high-end tests and has a presence in 200 cities, catering primarily to oncology through its vast network of oncologists. This offers Metropolis an immediate extension into specialized oncology testing, increasing its overall service offerings.

**Analyst Q&A Insights:**

- **Revenue and Profitability:** Analysts raised concerns regarding Core's historical profitability issues. Management cited high operating costs and the difficulty of single-specialty service models as key factors but expressed confidence in achieving significant margin improvements through synergies post-acquisition.

- **Market Position:** Analysts questioned competitive threats from expanding hospital chains; however, management underscored the continuous outsourcing of diagnostics by hospitals, making Metropolis’ specialized expertise indispensable.

- **Operational Risks:** Questions on potential integration challenges were addressed, with a focus on streamlining overlapping lab operations and leveraging existing resources.

- **Capital Allocation:** Analysts scrutinized the cash and stock financing mix for the acquisition. Management explained this strategy retains financial flexibility for future growth initiatives.

- **Long-Term Vision:** Management emphasized that the Core acquisition aligns well with their growth strategy focusing on specialty diagnostics, with a plan to scale operations efficiently.

**Market or Regulatory Updates:** No notable regulatory changes were discussed during the call.

**Strategic Focus Areas:** The management's emphasis on specialized oncology testing and strategic acquisitions highlights a clear focus on enhancing their market position and expanding operational capabilities.

**Investor Insight:** Given the favorable market dynamics, growth potential in oncology diagnostics, and a clear strategy for integration and profitability enhancement, there is an aligned sentiment towards a ‘buy’ position for Metropolis Healthcare shares, pending the successful execution of integration initiatives and realignment of Core's operations.